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Early remodeling of lower extremity vein grafts:
Inflammation influences biomechanical adaptation
Christopher D. Owens, MD, Frank J. Rybicki, MD, PhD, Nicole Wake, BS, Andres Schanzer, MD,
Dimitrios Mitsouras, PhD, Marie D. Gerhard-Herman, MD, andMichael S. Conte, MD, Boston, Mass
Background: The remodeling of vein bypass grafts after arterialization is incompletely understood. We have previously
shown that significant outward lumen remodeling occurs during the first month of implantation, but the magnitude of
this response is highly variable. We sought to examine the hypothesis that systemic inflammation influences this early
remodeling response.
Methods: A prospective observational study was done of 75 patients undergoing lower extremity bypass using autogenous
vein. Graft remodeling was assessed using a combination of ultrasound imaging and two-dimensional high-resolution
magnetic resonance imaging.
Results: The vein graft lumen diameter change from 0 to 1 month (22.7% median increase) was positively correlated with
initial shear stress (P  .016), but this shear-dependent response was disrupted in subjects with an elevated baseline
high-sensitivity C-reactive protein (hsCRP) level of >5 mg/L. Despite similar vein diameter and shear stress at
implantation, grafts in the elevated hsCRP group demonstrated less positive remodeling from 0 to 1 month (13.5% vs
40.9%, P  .0072). By regression analysis, the natural logarithm of hsCRP was inversely correlated with 0- to 1-month
lumen diameter change (P .018). Statin therapy (  23.1, P .037), hsCRP ( 29.7, P .006), and initial shear
stress (  .85, P  .003) were independently correlated with early vein graft remodeling. In contrast, wall thickness at
1 month was not different between hsCRP risk groups. Grafts in the high hsCRP group tended to be stiffer at 1 month,
as reflected by a higher calculated elastic modulus (E  50.4 vs 25.1 Mdynes/cm2, P  .07).
Conclusions: Early positive remodeling of vein grafts is a shear-dependent response that is modulated by systemic
inflammation. These data suggest that baseline inflammation influences vein graft healing, and therefore, inflammation
may be a relevant therapeutic target to improve early vein graft adaptation. (J Vasc Surg 2008;47:1235-42.)Vein graft caliber is regulated by a complex interplay of
hemodynamic stimuli, fluid-phase mediators, and vein wall
biology. Final lumen dimension is ultimately a balance
between the magnitude and direction of geometric remod-
eling. Using high-resolution duplex ultrasound (DUS) im-
aging, we have previously demonstrated that lower extrem-
ity vein grafts dilate significantly during the first month of
implantation, although considerable heterogeneity exists
despite similar anatomic and technical circumstances.1
The factors that regulate the adaptive remodeling of arte-
rialized veins are incompletely understood. After implanta-
tion, the thin-walled vein is subjected to an acute increase in
wall tension that induces a wall-thickening response.2 Early
vein lumen enlargement (positive lumen remodeling) is con-
jectured to be a flow-induced, endothelium-dependent re-
sponse to the acute increase in shear stress.1-4 Many other
factors, including pre-existing vein pathology, the extent of
operative injury, and themagnitude of the subsequent cellular
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Patients with advanced peripheral arterial disease
(PAD) undergoing lower extremity bypass reconstructions
have an inflammatory phenotype characterized by elevated
levels of markers such as high-sensitivity C-reactive protein
(hsCRP).5-9 We recently observed that among such patients,
those with an elevated preoperative hsCRP (5 mg/L) level
demonstrated an increased incidence of postoperative cardio-
vascular and vein graft related events.9 Themechanismunder-
lying this observation is unknown, however.
Endothelial dysfunction is an early manifestation of
atherosclerosis and linked to adverse clinical events. Nu-
merous investigators have noted an association between
CRP, reflecting systemic inflammation, and endothelial
dysfunction in the brachial artery.10,11 In patients under-
going coronary artery bypass grafting, CRP is independently
and negatively associated with ex vivo acetylcholine-induced,
endothelium-dependent relaxation of preimplantation vein
rings.12However,whether inflammation affects venous endo-
thelial function in vivo and towhat extent itmay influence vein
graft healing and changes in lumen caliber is currently un-
known. In the present study, we sought to examine the
hypothesis that systemic inflammation influences the early
lumen remodeling of lower extremity vein bypass grafts.
METHODS
Study design and population. This investigation was
designed as a substudy of a larger prospective study exam-
ining the relationship between systemic inflammation and
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bypass surgery with autogenous vein. Details of the parent
study inclusion/exclusion criteria are published else-
where.1,9 Briefly, patients were eligible to participate in the
study if they were undergoing primary or redo lower ex-
tremity arterial reconstruction with autogenous vein for
either critical limb ischemia or lifestyle-limiting claudica-
tion.
Patients were excluded if a nonautogenous graft was
used for any portion of the bypass or if the patient was
unlikely to comply with the follow-up protocol. To ensure
that the preoperative hsCRP measurement represented the
patient’s true baseline inflammatory status and was not
reflective of an acute process, patients were excluded if
there was evidence of local or systemic infection, including
cellulitis, osteomyelitis, or deep space infection of the foot,
or if they required operative débridement before bypass
grafting. Other exclusion criteria included the use of im-
munosuppressive medication (ie, prednisone, cyclospor-
ine), recent acute illnesses such as myocardial infarction or
stroke, systemic illness such as malignancies, or major sur-
gery 30 days of the index bypass.
We designed this prospective imaging substudy to
characterize the patterns of vein graft remodeling and to
examine the association between biomarkers of inflamma-
tion andmeasurements of structural change in the graft. All
patients in the parent clinical study who were willing to
comply with the imaging protocol were invited to partici-
pate in the substudy. The study protocol included DUS
graft surveillance at 1, 3, 6, 9, and 12 months after surgery;
at each of these time points, additional DUSmeasurements
were obtained, as will be outlined. Patients were also asked
to undergo high-resolution magnetic resonance imaging
(MRI) of the grafts at 1, 6, and 12 months. Patients were
not eligible for the MRI subgroup if they had metal im-
plants or were claustrophobic or unable to lie in the gantry
for the required imaging acquisition time.
All participants in this study provided written informed
consent, and the protocol was approved by the Institutional
Review Board of the Brigham andWomen’s Hospital (Bos-
ton, MA). Subjects were provided financial compensation
for the additional time spent to acquire research imaging
data.
The current report focuses on an analysis of early (1
month) remodeling patterns in this population. The cohort
comprised 75 consecutive patients who consented to be in
the imaging substudy and had at least one research DUS
study in this early timeframe available for analysis. Of these,
62 subjects had DUS performed at the time of surgery, 51
had DUS data at 1 month, and 41 had a study DUS
performed at both the time of surgery and at 1month. Data
from patients who had a single DUS at one time point were
included for descriptive purposes to represent the popula-
tion at that particular point in time. Patients who had DUS
observations at both the time of surgery and 1 month were
used to characterize remodeling changes. Among these 75
patients, 28 also had MRI of the graft at the 1-month timepoint. Study enrollment began in February 2004 and was
closed for this analysis in December 2006.
Blood collection and assays for inflammatory
markers. Plasma and bloodwere collected on themorning
of the lower extremity bypass surgery by direct femoral vein
puncture after the patient was anesthetized and before any
surgical incision. Blood was collected into ethylenediami-
netetraacetic acid and citrate Vacutainer (BD Diagnostics,
Franklin Lakes, NJ) tubes and immediately iced. Tubes
were spun at 3000g for 20 minutes at 4 °C in a refrigerated
centrifuge. Baseline plasma samples were stored at80 °C
until analysis. Assays for hsCRP, serum amyloid A (SAA),
and fibrinogen were performed in a core laboratory using
validated, high-sensitivity assays, as previously described. 9
The upper limit of normal defined for the hsCRP assay in
this laboratory is 5 mg/L, a level that we used for dichot-
omization in some of the end point analyses.
Operating room procedure. The vein graft configu-
ration used for bypass grafting was left to the discretion of
the surgeon and depended on the availability of ipsilateral
great saphenous vein (GSV). In most patients, veins were
tunneled superficially for ease of graft surveillance; how-
ever, if a portion of the vein was tunneled in an anatomic
position, the index segment was chosen in a superficial
portion of the conduit. At the completion of the vascular
reconstruction, routine completion DUS imaging was per-
formed to evaluate for flow disturbances or areas of steno-
sis. All intra-operative images were obtained on an ATL
HDI 3000 scanner (Advanced Technology Laboratories,
Bothell, Wash) with a 10-MHz transducer.
Index segment. Once the clinical DUS scan was com-
pleted, we selected a straight, 5-cm-long, superficial seg-
ment of graft to serve as the index segment for serial
postoperative measurements of graft diameter. The index
segment was selected far enough away from either anasto-
mosis to minimize turbulent blood flow. Accurate spatial
registration of the index segment for subsequent examina-
tions was assured by carefully marking the distance between
the index segment and the proximal anastomosis as well as
another anatomic landmark (eg, scar or tibial tuberosity),
and by placing metallic clips on nearby side branches.
Schematic maps of the graft configuration and index seg-
ment location were made and shared among study person-
nel performing postoperative DUS scans and MRIs to
insure consistent interrogation of the index segment over
time.
The index segment lumen dimensions were then ob-
tained using a series of M-mode images with a cross-
sectional view of the vein graft, as previously described.1
Five lumen diameter measurements were taken at each of
five 1-cm incremental locations along the index segment.
These 25 measurements were then used to determine the
mean lumen diameter of the index segment for that exam-
ination.
To determine vein graft stiffness, a pulse wave velocity
(PWV) measurement of the vein graft was obtained, as
previously reported.13 First, the length of the graft was
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for all subsequent PWV calculations.
Next, waveforms of the graft were obtained 1 cm distal
to the proximal anastomosis and 1 cm proximal to the distal
anastomosis. A time delay between the internal ultrasound
scan electrocardiogram (ECG) trigger and the foot of the
Doppler waveform was measured with the waveform and
the ECG tracing simultaneously displayed. The PWV was
subsequently calculated as the distance (in meters) between
the proximal and distal measurement locations divided by
the time difference (in seconds) of the QRS-to-onset of
flow waveform at the proximal and distal ends of the graft.
At least 10 individual time delays were measured at each
location and averaged for this calculation.
Finally, a sagittal view of the index segment accompa-
nied by a gated-Doppler waveform was recorded for deter-
minations of volumetric flow and estimations of shear
stress, as described below.
Magnetic resonance imaging data acquisition. To
characterize wall thickness, the 28 eligible patients signed
informed consent for high-resolution MRIs of their bypass
grafts postoperatively. The MRIs were performed with a
1.5T GE Excite MR (GEMedical Systems Waukesha, Wis)
system equipped with 4-G/cm gradients capable of a slew
rate of 15-G/cm/ms. The body coil was used for radiofre-
quency transmission (maximum B1 250 mG), and a 5-inch
circular coil was used for radiofrequency reception. An
ECG-gated two-dimensional fast spin echo sequence with a
double inversion recovery black blood module was used for
T1-weighted (T1WI) and T2-weighted imaging (T2WI).
For T2WI, a frequency-selective fat suppression pulse was
used.
A 256  256 matrix with 10-cm field of view and four
signal averages per phase encode with the “no phase wrap
option” were used for both contrast weightings; 2.2-min
acquisition/slice, depending on heart rate and with a 1
(about 1 second) and 2 (about 2 seconds) R-R TR period
for T1- and T2WI, respectively. Effective echo times for
T1- and T2WI are 14 and 58 ms, respectively. Echo train
length was 8 for T1WI and 16 for T2WI, with 32-KHz and
16-KHz bandwidth, respectively. In the typical protocol,
five 4-mm-thick slices orthogonal to the graft, spaced 10
mm apart, were acquired sequentially over 10 to 11 min-
utes per contrast weighting.
Postacquisition measurements were performed by
direct planimetry using dedicated three-dimensional Vi-
tal Images 3.9 postprocessing software (Vital Images,
Minnetonka, Minn).
Follow-up imaging protocol. Postoperative exami-
nations were performed in the Brigham and Women’s
Hospital Vascular Laboratory. Subjects were examined at
rest and in a supine position to allow normalization of heart
rate and blood pressure. Clinical noninvasive graft evalua-
tion includes measurement of ankle-brachial indices and
DUS scans with peak systolic velocity maps. Once the
surveillance protocol was completed, the aforementioned
index segment was identified using the referenced external
landmarks or clips placed at the time of surgery. M-modediameter measurements, PWV, and time averaged flow
were obtained and calculated as for the intraoperative im-
aging study. If an index segment developed a lesion requir-
ing reintervention or the graft developed an occlusion, the
patient would be removed from the imaging substudy. No
graft occlusion developed in these patients.
Calculations. Calculations for wall stiffness were
based on modifications of the Moens-Koerteweg formula
(Equation 1),14 relating the elastic modulus of the vein
graft to overall stiffness,
E 2ri (PWV)2 ⁄ (re ri) (1)
Thickness (h) (re ri) (2)
Stiffness E h 2ri (PWV)2 (3)
where E is the elastic modulus,  is the density of blood
(1.050 g/cm3), re is the external radius, and ri is the
internal radius. External and internal radius and thereby
wall thickness (Equation 2) were determined by MRI. The
product of the elastic modulus and the thickness of the vein
represents the overall stiffness and is equal to the quantity
2ri (PWV)
2 (Equation 3).
Volumetric flow, Q, was calculated from commercially
available software, (Brachial Analyzer, Medical Imaging
Applications, Iowa City, Iowa), by integrating the area
under the velocity spectral waveform and dividing by the
time required to arrive at a time-averaged velocity. Mean
flowwas calculated bymultiplying the time-averaged veloc-
ity by the mean area of the lumen (as obtained from the
index segment M-mode measurements).
Mean shear stress was calculated according to the
Hagen-Poiseuille formula w  4Q/ri
3, where w is
shear stress in dynes/cm2 and mean volumetric flow is Q.
The viscosity of blood, , is assumed to be 0.035 poise.
The lumen radius, ri, is in cm.
Statistical methods. All values are represented as ei-
ther mean  standard error of the mean or median and
interquartile range (IQR), depending on their distribution.
Comparisons of measures between individual time points
between groups were made with the Student t test or
Kruskal-Wallis nonparametric one-way analysis of variance.
Relationships between remodeling metrics and inflam-
matory marker levels were evaluated either by dichotomiz-
ing the population according to the preoperative plasma
hsCRP levels9 or as a continuous variable with a natural
logarithmic transformation. Log transformation was neces-
sary to normalize its distribution. The Spearman rank cor-
relation was used to compare hsCRP levels and relevant
patient demographics.
Stepwise multivariable linear regression analysis15
was conducted to determine the independent contribu-
tion of variables within traditional cardiovascular risk
factors, inflammation, and hemodynamic categories to
percentage of lumen remodeling from 0 to 1 month. The
covariates with P 	 0.2 included in the final model were
age, diabetes, statin use, initial shear stress, CRP risk
group (elevated hsCRP 
5 mg/L or 5 mg/L), or the
natural logarithm of hsCRP (ln-hsCRP). C-reactive pro-
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(high or low) or continuous variable, and both -coeffi-
cients are presented.16 Colinearity between explanatory
variables was assessed by calculating variance inflation
factors. The -coefficient, confidence intervals, and
P values are presented. Values of P 	 .05 were consid-
ered significant. Statistical analyses were performed on
Intercooled Stata 7.0, (Stata Corp, College Station,
Tex).The authors had full access to and take full respon-
sibility for the integrity of the data.
RESULTS
Patient demographics and risk factors. The mean
age for the study cohort was 68.8  11.1 years. Of the 75
subjects, 42 (56.0%) were men, 58 (79.5%) were white, 38
(51.4%) had diabetes mellitus, 44 (59.5%) had known
history of coronary artery disease, 5 (6.7%) had end stage
renal disease, and 58 (77.3%) were taking a 3-hydroxy-3
methyl-glutaryl-coenzyme A (HMG-CoA) reductase in-
hibitor (statin).
Surgical procedures. The indication for the revascu-
larization was critical limb ischemia (CLI), defined as rest
pain or tissue loss, in 44 subjects (58.7%), claudication in
26 (36.0%), and repair of popliteal aneurysm in five (6.7%).
Autogenous conduits included single-segment GSV (re-
versed or nonreversed) in 57 cases (76.0%), spliced great
saphenous or small saphenous vein in 6 (8.0%), single-
segment arm vein in 4 (5.3%), and spliced arm vein in 8
(10.7%). Inflow sites included the common femoral artery
in 50 patients (66.7%), superficial femoral artery in 17
(22.7%), or popliteal artery in eight (10.7%). Distal anasto-
moses were performed to the popliteal artery in 39 patients
(52.0%), to the tibial artery in 24 (32.0%), and to a pedal
artery 12 (16.0%).
Inflammation and remodeling. The median hsCRP
value for the entire cohort was 3.25 mg/L (IQR, 1.38-
14.20). The median concentration was 0.94 mg/dL (IQR,
0.56-2.85) for SAA and 472.75 (IQR, 404.8-610.2) for
fibrinogen. High-sensitivity CRP correlated with the pres-
ence of diabetes (R  0.29, P  .0007), chronic kidney
disease classification (R  0.34, P  .0001), and critical
Table I. Morphometrics of lower extremity vein grafts
Vein graft metrics
High-resolution ultrasound imaging, (N)
Lumen diameter (surgery), mm  SEM
Lumen change (0-1 mon), %  SEM
Shear stress (surgery), dynes/cm2  SEM
2D magnetic resonance imaging, (N)
Wall thickness (1 mo.), mm  SEM
Elastic modulus (1 mo.), Mdynes/cm2  SEM
CRP, C-reactive protein; 2D, two-dimensional.
P values are comparisons for high vs low high-sensitive CRP groups.
28 patients were enrolled in a magnetic resonance imaging substudy.limb ischemia (R  0.35, P 	 .00001). In contrast withhsCRP, neither fibrinogen nor SAA were predictive of any
imaging endpoints.
Vein graft morphometrics are summarized in Table I.
Fig 1. A,Mean index segment lumen percentage change dichot-
omizing the population by high-sensitivity C-reactive protein
(hsCRP) levels of 5 mg/L vs elevated levels of 
5 mg/L. Less
outward lumen remodeling was demonstrated in those subjects
with elevated hsCRP levels (P  .0072). Data are presented with
the standard error of the mean. B, Linear regression of natural-
logarithmic transformed hsCRP levels (ln-hsCRP) and the per-
centage lumen change from the time of surgery to 1 month (R 
0.371, P  .018).
High-sensitive CRP
5 mg/mL Elevated P
24 16
3  1.43 3.71  .82 .696
8  7.0227 13.54  5.25 .0072
3  3.56 24.93  3.00 .566
11 17
5  .05 .72  .04 .685





25.0For the entire cohort, the mean lumen diameter of the
R  0
JOURNAL OF VASCULAR SURGERY
Volume 47, Number 6 Owens et al 1239index segment was 3.77  0.14 mm at implantation, and
this increased to 4.67  0.16 mm during the first month
after surgery (P .0001). The mean index segment lumen
dilation (relative change) from the time of surgery to 1
month was 30.6%  32.3% (median, 22.7%; IQR, 7.1%-
48.7%). No difference was found in the starting lumen
diameters between patients in the low vs the elevated (
5
mg/L) hsCRP groups (3.83  1.43 mm vs 3.71  .82
mm). During the first postoperative month, however,
grafts in the low hsCRP group demonstrated greater me-
dian lumen enlargement, at 37.2% (40.9%  34.4%) vs
9.49% (13.5%  21.0%; P  .0072; Fig 1, A). Analyzing
baseline hsCRP as a continuous risk variable, we observed a
strong negative relationship between ln-hsCRP values and
the percentage change in the index segment lumen diame-
ter during this period (R  0.40, P  .010, Fig 1, B).
The mean initial shear stress for the entire cohort was
26.7  1.9 dynes/cm2 and decreased to 20.5  2.3
dynes/cm2 during the first month of implantation (P 
.05). No significant differences were found in the initial
shear stress between grafts in the elevated hsCRP popula-
tion vs those whose hsCRP was5 mg/L. During the first
month of implantation, initial shear stress positively corre-
lated with lumen dilation (R  .36, P  .025, Fig 2, C).
The association between initial shear stress and lumen
dilation was relatively robust in subjects whose hsCRP level
was 5 mg/L (R  .50, P  .015, Fig 2, B), but the
association was not seen in patients with elevated hsCRP
(R  .03, P  .926; Fig 2, C).
A multivariable analysis was undertaken to assess vari-
ables contributing to early (1 month) vein graft remod-
eling (Table II). Significant variables included patient age
(P  .016), hsCRP risk group (P  .006), initial shear
stress (P  .003), and current statin therapy (P  .037).
These four variables accounted for approximately 45% of
the variability in lumen dilation between surgery and 1
Fig 2. A, Linear regression of the entire population co
dilation from 0 to 1 month (R  0.387, P  .016). B
(hsCRP)5 mg/L (R 0.5, P .014) and (C) subset o
of correlation between initial shear and lumen dilation (month. Of importance, conduit type (ie, type or orienta-tion of the vein), diabetes, or sex did not significantly add to
the model. When modeling for the final 1-month lumen
diameter (Table II), initial diameter, CRP risk group, and
statin use were independently predictive.
In a subset of 28 patients who agreed to participate in
the MRI examinations, the vein graft wall thickness at 1
month after implantation was assessed by T2WI (Fig 3). No
difference was found in either total wall thickness or total
wall area between high vs low hsCRP risk groups (Table I).
There was, however, a trend toward increased modulus of
elasticity at 1 month in the high hsCRP group (50.44 
12.22 vs 35.05 6.51Mdynes/cm2, P.069), suggestive
of greater conduit stiffness.
DISCUSSION
This study demonstrates that in human lower extremity
vein grafts, rapid lumen remodeling, which occurs within
the first month after surgical implantation, is significantly
modulated by systemic inflammation. Vein grafts in pa-
tients with baseline hsCRP values 	5 mg/L had signifi-
cantly more early lumen dilation than those within the
ring initial shear stress and mean index segment lumen
set of patients with high sensitivity C-reactive protein
ients with elevated hsCRP
5 mg/L demonstrating loss
.103, P  .725).
Table II. Multivariable regression of variables
influencing lumen diameter changes in vein grafts,
0 to 1 month
Variable  (95% CI) P
Elevated CRP 29.7 (50.5 to 8.9) .006
Ln-CRPa 10.8 (18.2 to 3.6) .002
Statin 23.1 (1.5 to 44.2) .037
Initial shear 0.84 (0.32 to 1.4) .003
Age 1.17 (0.23 to 2.1) .016
CI, confidence interval; CRP, C-reactive protein.
aModel created with either CRP as a dichotomized or natural log (ln)
transformation variable.mpa
, Sub
f patelevated hsCRP group, and there was a negative linear
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ing. Furthermore, within the elevated hsCRP group, the
positive correlation between shear stress and outward lu-
men remodeling was not seen, suggesting a level of dys-
function in either shear stress-signal transduction or vessel
response. Moreover, in the multivariable regression model,
baseline hsCRP was independently and negatively associ-
ated with early diameter change. Notably, the significance
of the hsCRP variable was not attenuated with the inclusion
of traditional cardiovascular risk factors into the model.
Conversely, use of statins, a class of agents known to reduce
inflammation and improve endothelial function, was posi-
tively correlated with early lumen dilation.
Although preliminary, these results begin to integrate
data from the domains of biomechanical, biochemical, and
traditional cardiovascular risk factors to predict early
changes in the vein graft lumen. A regression equation
using four explanatory variables such as, lumen change 
10.9 (ln-hsCRP)  23.1 (presence of statin)  0.85
(initial shear stress) 1.17 (age) 72.5, accounts for 45%
of the variance seen in early lumen caliber change, which is
a substantial improvement over any one factor alone. To
our knowledge, this is the first report of an in vivo link
between inflammation and early lumen remodeling in
peripheral bypass grafts. However, of the three markers
of inflammation that were measured—CRP, SAA, and
fibrinogen—only CRP had a negative association with
vein graft lumen changes.
Inflammation and endothelial function. Patients
with PAD have a pro-inflammatory phenotype that mani-
fests as higher circulating levels of hsCRP compared with
matched controls without PAD.17 This is confirmed in the
present report, where the median hsCRP level was found to
be 3.25 mg/L, which places this cohort in the highest risk
category as defined for the Centers for Disease Control and
Prevention.9,18 Inflammation quantified by hsCRP has
been shown to be associated in vivo with impaired brachial
artery flow-mediated, endothelium-dependent, vasodila-
tion in patients with PAD7 and blunted coronary endothe-
lial vasoreactivity in patients with coronary artery disease.11
Fig 3. A, This image is a representative example of a high-
resolution two-dimensional magnetic resonance T2-weighted im-
age using black blood module of a human saphenous vein graft.
B, The area inscribed by the two lines represents the T2-weighted
wall area. The lumen area is 0.327 cm2, and the total vessel area is
0.566 cm2.These observations suggest that inflammation impairs arte-rial endothelial function. In patients undergoing coronary
artery bypass graft surgery, circulating plasma CRP concen-
trations result in venous endothelial dysfunction and im-
paired acetylcholine-induced, endothelium-dependent re-
laxation of preimplantation vein graft rings ex vivo
(r0.30, P .02).12 Further investigations are needed to
characterize endothelial function in vein bypass grafts and
to determine its relationship to the inflammatory response,
structural remodeling, and clinical outcomes.
In vivo measurements of remodeling. Despite the
clinical importance of vein graft disease, relatively little
attention has been given to in vivo measurements of human
vein graft remodeling. Most reports to date have involved
intravascular ultrasound examinations of aortocoronary by-
pass grafts, which have the advantage of adequate echo-
differentiation between the vein graft adventitia and sur-
rounding pericardial tissue so that wall thickness
measurements may be obtained.19-22 Collectively, these
reports demonstrate that the mechanisms of saphenous
vein graft narrowing in the coronary circulation are often a
combination of negative remodeling and intimal hyperpla-
sia. Although somewhat conflicting, these studies also dem-
onstrate that saphenous vein grafts are capable of dilating to
some degree in the face of an encroaching intimal hyper-
plastic lesion or atherosclerotic plaque. Consistent with
these findings, Lau et al,23 using a noncontrast, ECG-
gated, cardiac computed tomography scanner, demon-
strated a decrease in total vessel diameter of 
5% (defined
as negative remodeling) in 62% of aortocoronary vein
grafts. Notably, none of these studies used serial imaging
beginning at the time of implantation. More effort is clearly
needed to accurately document remodeling characteristics
of both coronary and lower extremity vein grafts and to
determine the extent maladaptive remodeling contributes
to vein graft failure.23
Even fewer studies have focused on the structural
changes of peripheral vein grafts. Fillinger et al4 demon-
strated a positive correlation between shear stress and the
percentage change in lumen caliber during the first year of
implantation. Leotta et al24 observed negative lumen re-
modeling by three-dimensional lumen reconstructions of
lower extremity saphenous vein graft revisions (patch an-
gioplasties). There was an average loss of lumen cross-
sectional area by 31% during a 35-week period. However,
the average postoperative lumen diameter after patching
was 7.5 mm, which was considerably larger than the unre-
vised vein grafts presented in our current report.24 Neither
study was able to measure the vein graft wall, illustrating
the technical difficulty in resolving the structure.
Limitations. Our characterization of vein graft re-
modeling currently focuses on the combined use of ad-
vanced noninvasive imaging tools, in particular the optimi-
zation of high-resolution MRI, to attain an accurate
assessment of wall thickness, which has eluded us with
conventional DUS technology. This will allow temporal
assessment of wall structural and total vessel area rather
than changes in lumen diameter. Limitations related to
assumptions of the Moens-Korteweg equation, and there-
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tions, have been detailed elsewhere.1,13 Briefly, theMoens-
Korteweg equation assumes a thin-walled, nontapered tube
containing an ideal noncompressible liquid. The PWV is an
integrated value over the entire vein graft and fails to
account for heterogeneity in viscoelastic properties within
the vein graft that may predispose it to local failure at
susceptible sites. Despite these limitations, PWV is used
extensively in the literature and is one of the most accurate
noninvasive methodologies to assess stiffness.
Although this study was not sufficiently powered to
detect differences in patency between vein grafts that did
and did not undergo favorable lumen remodeling, it sug-
gests that inflammation has a detrimental effect on the
vein’s ability to function as an arterial substitute, whichmay
ultimately impact patency. Finally, limited sample size and
missing observations might have introduced bias and con-
founded our results.
Postoperative wound complications accounted for
most of the missing DUS data. Other reasons included one
patient who died, two patients experienced early graft
occlusion, and the remainder had scans that were uninter-
pretable, returned outside of their 1-month study window
(2 weeks), or the study staff was unavailable. Of the many
methods to handle missing values, including last observa-
tion carried forward, imputation (mean or regression), or
list-wise omission,25 we favored the latter because no dis-
cernible differences existed in terms of cardiovascular risk
factors and levels of inflammation between those patients
with missing values and those with all observations present.
CONCLUSIONS
This study confirms that lower extremity vein grafts
undergo significant lumen remodeling within the first
month of implantation and that shear stress is strongly
correlated with early changes in lumen caliber. We now
report that baseline systemic inflammation, as reflected by
hsCRP, appears to be an important modifier of this early
hemodynamic response. This finding may have important
clinical and therapeutic implications. Further effort is
needed to characterize the temporal and spatial remodeling
of the lumen and wall of peripheral vein grafts and to
determine early remodeling signatures of healthy versus
diseased grafts.
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RECOUP THE LOUPES 
Despite extremely limited resources, surgeons in developing countries work to provide their 
patients with the best possible care. For many of these surgeons, technology such as loupes, 
which facilitate delicate procedures, is simply out of reach.  
One year ago, Loupes Around The World distributed its first pair of loupes to a plastic surgeon
in Phnom Penh, Cambodia. Before Loupes Around The World, this surgeon commonly 
repaired cleft lips and palates, and treated trauma patients with maxillofacial injuries without 
the benefit of surgical magnification. Since then, this not-for-profit organization has provided 
loupes to surgeons from Panama to India and continues to receive requests from surgeons 
around the world.  
Loupes Around The World is now recycling donated loupes via a program called “Recoup the 
Loupes.” Surgeons with unused loupes are asked to send them to the foundation; there, repairs 
can be made to adjustable loupes, and the telescopes from fixed loupes can be installed into 
new lenses and frames. For fixed loupes, optical measurements are taken to ensure that the 
loupes will meet the needs of each individual surgeon. 
Please send your unused loupes to:  
David C. Knight, M.D., F.A.C.S. 
Loupes Around The World 
c/o Surgical Associates of Waterbury 
1211 West Main St. 
Waterbury, CT 06708 
Loupes Around The World accepts loupes made by any manufacturer. For more information 
about Loupes Around The World, as well as information about how to contribute, please visit: 
www.loupesaroundtheworld.org. Upon receiving loupes, a letter of acknowledgment will be 
sent to the donor for tax purposes. Loupes Around the World is a 501(c)3 tax-exempt 
organization.  
